ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)

Coronavirus SARS-CoV-2
01/05/2022 - 30/04/2025
Ibrahim Abubakhar (University College of London - UCL)
Funded by
European Commission, Horizon 2021-2024

The END-VOC consortium will support the European and global response to the COVID-19 pandemic and Variants of Concern (VOC) through well-characterised cohorts and linked with existing European and international initiatives.

END-VOC consists of 19 partners in Europe (UK, Spain, Italy, Germany, Netherlands, Norway, Italy), South America (Brazil and Peru), Africa (Mozambique, South Africa, Nigeria and 13 ANTICOV African countries), Middle East (Palestine) and Asia (India, Pakistan, Philippines) with a focus on countries affected by VOCs and VOIs.


The project aims to elucidate the global circulation of the current and emerging SARS-CoV-2 VOCs and their characteristics, including transmissibility, pathogenicity and propensity to cause reinfection, to support best control strategies and the development of diagnostics; evaluate the impact of VOCs on the effectiveness of different vaccines and vaccination strategies, and assess the implications of VOCs on the choice of optimal treatment options.

END-VOC will also investigate how VOCs alter long-term post-infection sequelae and where new VOCs emerge within hosts using our clinical cohorts.

The project will inform future preparedness and response by working closely with international and national public health organisations and existing cohort consortia. Specific beyond state-of-the-art components of END-VOC include the use of novel phylogenetic prediction tools and mathematical modelling; generation of powerful cohorts through sentinel surveillance in low and middle-income settings and cohorts of travellers to increase our global reach; use of novel predictive modelling of clinical outcomes by VOC and comorbidity/treatment and evaluation of differences in natural and vaccine immunity by VOC; antiviral screening models within cohorts and artificial intelligence-driven tool for the prediction of long COVID.

Total Funding

9,997,114 €

Our Team

Coordinator (ISGlobal)

ISGlobal Team

See More

Other projects

See Past Projects


Combating Bacterial Resistance In Europe


Combatting Bacterial Resistance in Europe - Carbapenem Resistance


Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique


Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals


Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique


Integrating and decentralizing diabetes and hypertension services in Africa


Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.


Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo

AMR DetecTool

A breakthrough device for the rapid detection of antimicrobial resistance


Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19


Hepatitis B Virus COMmunity Screening and Vaccination in Africans


Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

Hep C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.


Close the Gap, Increase Access, Provide Adequate Therapy


Strengthening Epidemiological Surveillance in Benin and Burkina Faso for an Effective Response to COVID-19


Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia


Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status


Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring